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The European Society of Cardiology (ESC) and 
the European Heart Rhythm Association (EHRA) have 
developed the 2010 Clinical Practice Guidelines 
covering atrial fibrillation (AF),1 the most common 
cardiac arrhythmia occurring in 1-2% of the general 
population. Advance has been made regarding the 
dynamic development of AF from a preclinical state to 
an irreversible cardiac arrhythmia and a novel 
classification of AF has been adopted based on the 
presentation and duration of the arrhythmia: first 
diagnosed, paroxysmal, persistent, long-standing 
persistent and permanent AF are the 5 types of AF in 
use for clinical management of patients with AF. 
Structural and electrical remodelling are hallmarks 
of the pathophysiological changes facilitating the 
initiation and perpetuation of AF. While atrial fibrosis 
was the main cause of nonhomogeneity of conduction 
according to earlier ESC guidelines, nowadays any kind 
of structural abnormality (inflammatory changes, 
amyloid deposit, apoptosis, necrosis, hypertrophy, 
microvascular changes, etc.) is believed to trigger the 
electrical dissociation between muscle bundles and 
permit small re-entrant circuits to stabilize the 
arrhythmia.2 The adage ‘atrial fibrillation begets atrial 
fibrillation’ describes electrical remodelling due to 
shortening of atrial refractory period, which is 
attributed to down-regulation of the L-type Ca2+ inward 
current and up-regulation of inward rectifier K+ 
currents. Although the exact role of the genome in the 
pathogenesis of AF is not known, numerous inherited 
cardiac syndromes and mutations have lately been 
associated with AF and should be elucidated. Mutations 
in the gene coding for atrial natriuretic peptide, loss of 
function mutations in the cardiac sodium channel gene 
SCN5A or gain of function mutations in the cardiac 
potassium channel are related to familial AF and 
genetic loci close to the PITX2 and ZFHX3 genes are 
currently associated with enhanced risk for 
cardioembolic stroke.  
A new simple clinical tool for the diagnostic 
evaluation of patients with the ‘arrhythmia absoluta’ 
has been introduced in the present guidelines, the 
EHRA score,3 which drives the decision for acute 
restoration of sinus rhythm or acute management of 
ventricular rate depending on the severity of symptoms. 
Patients with different types of AF are regarded to have 
a risk for stroke and thromboembolism according to 
their ‘major’ (previously referred to as ‘high’: previous 
stroke/TIA or systemic embolism, age≥75 years) and 
‘clinically relevant non-major’ (previously referred to 
as ‘moderate’: heart failure or severe LV systolic 
dysfunction, hypertension, diabetes mellitus, age 65-74 
years, female sex, vascular disease) risk factors no 
matter whether they suffer from paroxysmal, persistent 
or permanent AF. The 2006 guidelines for the 
management of AF introduced the CHADS2 score and 
the 2010 guidelines recommend its use particularly to 
primary care physicians and non-specialists, because it 
is a simple and easily remembered score of assessing 
stroke risk and beginning oral anticoagulant therapy 
(OAC) when CHADS2 score ≥2 (Table 1). In patients 
with a CHADS2 score of 0-1 it is recommended to use 
the CHA2DS2-VASC score4 which provides a more 
detailed stroke risk assessment, taking into account 
congestive heart failure, hypertension, age ≥75 
(doubled), diabetes, stroke (doubled), vascular disease, 
age 65-74 and sex category (female). Patients with 
CHA2DS2-VASC score 1 should take either OAC or 
aspirin 75-325 mg/day, while those with score 0 should 
rather take no antithrombotic therapy (Table 2). An 
assessment of bleeding is essential at the initiation and 
follow-up of antithrombotic therapy; the HAS-BLED 
score (hypertension, abnormal renal/liver function, 
stroke, bleeding history or predisposition, labile INR, 
elderly >65 years, drugs or alcohol consumption) 
derived from the EuroHeart Survey,5 is a simple score 
recommended in current guidelines for anticoagulated 
patients (score ≥3 indicates caution and regular review 
of INR) (Table 3). Patients with AF and primary 
percutaneous coronary intervention (PCI) due to acute 
ST (or non-ST) segment elevation myocardial 
infarction should take triple therapy (VKA, aspirin and 
clopidogrel) in the initial period (3-6 months) or for 
longer in selected patients at low bleeding risk, 
followed by longer therapy (up to 12 months) with 
VKA plus clopidogrel 75 mg/day (or alternatively 
aspirin 75-100 mg/day). In patients with AF and 
elective PCI with bare-metal stents, triple therapy 
(VKA, aspirin and clopidogrel) is recommended for 4 
weeks, followed by long-term therapy (12 months) with 
VKA plus clopidogrel 75 mg/day (or alternatively 
aspirin 75-100 mg/day).When drug-eluting stents are 
used, triple therapy should be administered for ≥3 
months for an ‘-olimus’ (sirolimus, everolimus, 
tacrolimus) type eluting stent and at least 6 months for 
a paclitaxel eluting stent.6 In the RELY study 
dabigatran 110 mg twice daily was non-inferior to 
VKA for the prevention of stroke/systemic embolism 
and had lower rates of major hemorrhage compared 
with VKA. 
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Table 1. CHADS2 score parameters 
 
 
Table 2. CHA2DS2-VASC score definition 
 
 
Table 3. HAS-BLED score definition 
 
Apart from adequate antithrombotic therapy, at the 
beginning of patients’ management, a decision should 
be made upon the restoration and maintenance of sinus 
rhythm. The Atrial Fibrillation Follow-up Investigation 
of Rhythm Management (AFFIRM)7, the RAte Control 
versus Electrical cardioversion for persistent atrial 
fibrillation (RACE)8, the Pharmacologic Intervention in 
Atrial Fibrillation (PIAF)9 and the Strategies of 
Treatment of Atrial Fibrillation (STAF)10 trials found 
no differences in quality of life between rhythm and 
rate control. Although expected at the outset of trials, 
development of heart failure and mortality were not 
different between rate and rhythm control in the 
AFFIRM, RACE or Atrial Fibrillation and Congestive 
Heart Failure (AF-CHF)11 trials; post-hoc analysis 
suggests that deleterious effects of antiarrhythmic drugs 
and progression of underlying cardiac disease explain 
these findings. Furthermore, previous guidelines 
recommended strict rate control (60-80 bpm at rest, 90-
115 bpm during exercise) but the RACE II12 trial did 
not identify a benefit of strict over lenient (initially 
aiming at resting heart rate <110 bpm and further 
reduction of ventricular rate until symptoms become 
tolerable) rate control. Apart from β-blockers and non-
dihydropyridine calcium channel blockers that are 
useful in both acute and long-term rate control, 
amiodarone is an effective rate control drug (usually 
initiated for rhythm control, it may be continued for 
patients who have lapsed into permanent AF only when 
safer agents are unsuitable)1 and a new drug, 
dronedarone, may also effectively reduce heart rate at 
rest, during exercise and during AF relapses. The 
choice of rhythm control therapy depends on 
underlying heart disease and includes dronedarone, 
which inhibits sodium – potassium – calcium channels 
and was proven to be less effective in the maintenance 
of sinus rhythm but also less toxic than amiodarone in 
the DIONYSOS trial.13 Current guidelines recommend 
dronedarone as the first antiarrhythmic option for 
patients with symptomatic AF and underlying 
cardiovascular disease due to its safe and effective 
profile (ATHENA trial),14 although dronedarone is 
contraindicated in patients with NYHA III-IV or 
recently decompensated heart failure (ANDROMEDA 
trial),15 where amiodarone should be used. Vernakalant 
is also mentioned as a drug recently approved which 
can be used for acute termination of recent-onset AF in 
patients with lone AF, AF associated with 
hypertension, stable coronary artery disease or mild to 
moderate heart failure. 
When electrical or pharmacological cardioversion 
is decided, anticoagulation is considered mandatory: for 
AF < 48 h treatment with unfractionated heparin (UFH) 
or low-molecular weight heparin (LMWH), for AF of 
>48 h or AF of unknown duration, VKA treatment 
should be given for at least 3 weeks before 
cardioversion and a transesophageal echocardiogram 
should be performed to exclude left atrial (LA) or LA 
appenadage thrombus, spontaneous echo-contrast or 
complex aortic plaque. Recent guidelines are quite 
strict as far as anticoagulation is concerned, suggesting 
that VKA should be continued for a minimum of 4 
weeks after cardioversion (due to ‘atrial stunning’) and 
life-long in patients with risk factors for stroke or AF 
recurrence. 
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In patients who remain symptomatic despite 
optimal medical therapy (including rate and rhythm 
control), catheter ablation should be reserved. It is clear 
that patients with heart failure benefit from AF ablation 
(e.g. improvement of ejection fraction/exercise 
tolerance) while no benefit has been demonstrated for 
asymptomatic patients. Another intervention included 
in recent guidelines is ablation of the atrioventricural 
node, a palliative and irreversible procedure that is 
reasonable when pharmacological rate control is not 
possible; selection of the appropriate cardiac implant 
depends on the type of AF and the presence/severity of 
associated heart disease (patients with reduced LV 
function may require biventricular pacing). 
Finally, the 2010 guidelines introduced ‘upstream 
therapy’ to prevent or delay myocardial remodelling 
causing the development of AF (primary prevention) 
and reduce AF recurrence and progression to permanent 
AF (secondary prevention). Upstream therapy for AF 
includes treatment with angiotensin-converting enzyme 
inhibitors (ACEIs), angiotensin receptor blockers 
(ARBs), aldosterone antagonists, statins and omega-3 
polyunsaturated fatty acids (PUFAs). In particular, 
ACEIs and ARBs are recommended for prevention of 
new-onset AF in patients with underlying heart disease 
(e.g. left ventricular hypertrophy, reduced ejection 
fraction) but evidence is less robust in secondary 
prevention. Statin therapy is reported to be effective in 
prevention of post-operative AF and more studies are 
required to define the role of aldosterone antagonists 
and PUFAs in prevention of AF.   
 
REFERENCES 
 
1. Camm AJ, Kirchhof P, Lip G et al: Guidelines for the 
management of Atrial Fibrillation. The Task Force for 
the Management of Atrial Fibrillation of the European 
Society of Cardiology (ESC) developed with the special 
contribution of the European Heart Rhythm Association 
(EHRA). Eur Heart J 2010; 31: 2369-2429. 
2. Schotten U, Verheule S, Korchhof P, Goette A: 
pathophysiological mechanisms of atrial fibrillation - a 
translational appraisal. Physiol Rev 2011; 91: 265-325 
3. Kirchhof P, Auricchio A, Bax J et al: Outcome 
parameters for trials in atrial fibrillation: executive 
summary. Recommendations from a consensus 
conference organized by the German Atrial Fibrillation 
Competence NETwork (AFNET) and the European 
Heart Rhythm Association (EHRA). Eur Heart J 2007; 
28:2803–2817.  
4. Lip GY, Nieuwlaat R, Pisters R et al: Refining clinical 
risk stratification for predicting stroke and 
thromboembolism in atrial fibrillation using a novel risk 
factor-based approach: the Euro Heart Survey on atrial 
fibrillation. Chest 2010; 137:263–272. 
5. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-
friendly score (HAS-BLED) to assess one-year risk of 
major bleeding in atrial fibrillation patients: The Euro 
Heart Survey. Chest 2010; 138: 1093-1100. 
6. Lip GY, Huber K, Andreotti F, et al. Management of 
antithrombotic therapy in atrial fibrillation patients 
presenting with acute coronary syndrome and/or 
undergoing percutaneous coronary intervention/ 
stenting. Thromb Haemost 2010; 103:13–28. 
7. AFFIRM Investigators. A comparison of rate control 
and rhythm control in patients with atrial fibrillation. N 
Engl J Med 2002; 347:1825–1833. 
8. Van Gelder IC, Hagens VE, Bosker HA, et al. A 
comparison of rate control and rhythm control in 
patients with recurrent persistent atrial fibrillation. N 
Engl J Med 2002; 347:1834–1840. 
9. Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate 
control in atrial fibrillation—Pharmacological 
Intervention in Atrial Fibrillation (PIAF): a randomized 
trial. Lancet 2000; 356:1789–1794. 
10. Carlsson J, Miketic S, Windeler J, et al. (STAF 
Investigators): Randomized trial of rate-control versus 
rhythm control in persistent atrial fibrillation. J Am Coll 
Cardiol 2003; 41: 1690–1696. 
11. Roy D, Talajic M, Nattel S t al: Rhythm control versus 
rate control for atrial fibrillation and heart failure. N 
Engl J Med 2008; 358: 2667–2677. 
12. Van Gelder IC, Groenveld HF, Crijns HJ et al: Lenient 
versus strict rate control in patients with atrial 
fibrillation. N Engl J Med 2010; 362: 1363–1373. 
13. Le Heuzey J, De Ferrari GM, Radzik D et al: A short-
term, randomized, double-blind, parallel-group study to 
evaluate the efficacy and safety of dronedarone versus 
amiodarone in patients with persistent atrial fibrillation: 
the DIONYSOS study. J Cardiovasc Electrophysiol 
2010; 21: 597–605. 
14. Hohnloser SH, Crijns HJ, van Eickels M et al: Effect of 
dronedarone on cardiovascular events in atrial 
fibrillation. N Engl J Med 2009; 360: 668–678. 
15. Kober L, Torp-Pedersen C, McMurray JJ et al: Increased 
mortality after dronedarone therapy for severe heart 
failure. N Engl J Med 2008; 358: 2678–2687. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
